Screening with annual transvaginal ultrasound (TVU) and CA125 is ineffective at detecting early-stage ovarian cancer in both high- and low-risk women, according to the findings of a retrospective audit study involving 341 asymptomatic women.
Screening with annual transvaginal ultrasound (TVU) and CA125 is ineffective at detecting early-stage ovarian cancer in both high- and low-risk women, according to the findings of a retrospective audit study involving 341 asymptomatic women.
In breaking down the participants, 179 of the women had more than a 10% lifetime risk of developing ovarian cancer, 77 fell into a moderate risk group (4%-0% lifetime risk), and 71 had less than a 4% lifetime risk.
Thirty women underwent exploratory surgery because of abnormal findings, but only two had cancer, and only one had ovarian cancer; the other had endometrial cancer.
The researchers calculated the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for TVU in the whole cohort to be 33.3%, 85.8%, 0.6%, and 99.8%, respectively. For those at high risk, the same figures for TVU were 33.3%, 84.5%, 1.1%, and 99.6%, respectively. The values for both modalities for the entire study population were 66.7%, 82.9%, 1.5%, and 99.8%, respectively. The values for both modalities applied to the high-risk group alone were 50%, 82.8%, 1.3%, and 99.7%, respectively.
Woodward ER, Sleightholme HV, Considine AM, et al. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG. 2007;114:1500-1509.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More